chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: COVID19
Symptoms: Feeling hot, Injection site erythema, Injection site pain, Pain in extremity
Clinical narrative: WARM; ARM HURTS UPON TOUCH; INJECTION SITE PAIN; INJECTION SITE REDNESS; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported,) dose was not reported, administered on 10-MAR-2021in left arm for prophylactic vaccination.  The batch number was not reported and has been requested. No concomitant medications were reported.  On MAR-2021, the subject experienced warm. On MAR-2021, the subject experienced arm hurts upon touch. On MAR-2021, the subject experienced injection site pain. On MAR-2021, the subject experienced injection site redness. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from arm hurts upon touch, and injection site pain, and the outcome of injection site redness and warm was not reported. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pruritus
Clinical narrative: FEELING ITCHY AROUND HER MOUTH, LOWER BACK, AND THE ARM; NAUSEA; This spontaneous report received from a patient concerned a patient of unspecified age. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805020, and batch number: 1805020 expiry: UNKNOWN) dose was not reported, administered on 14-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 14-MAR-2021, the subject experienced feeling itchy around her mouth, lower back, and the arm. On 14-MAR-2021, the subject experienced nausea. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from nausea on 14-MAR-2021, and the outcome of feeling itchy around her mouth, lower back, and the arm was not reported. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Chills, Hypersomnia, Pain, Pyrexia
Clinical narrative: CHILLS; FEVER; BODY ACHES; SLEPT 24 HOURS; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown, expiry: UNKNOWN) dose was not reported, administered on 12-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On MAR-2021, the subject experienced chills. On MAR-2021, the subject experienced fever. On MAR-2021, the subject experienced body aches. On MAR-2021, the subject experienced slept 24 hours. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the chills, fever, body aches and slept 24 hours was not reported. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Chills, Nausea, Pain, Pyrexia
Clinical narrative: BODY ACHES; CHILLS; LOW GRADE FEVER; NAUSEA; This spontaneous report received from a patient via a company representative concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On 14-MAR-2021, the subject experienced body aches. On 14-MAR-2021, the subject experienced chills. On 14-MAR-2021, the subject experienced low grade fever. On 14-MAR-2021, the subject experienced nausea. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the body aches, chills, low grade fever and nausea was not reported. This report was non-serious.
Sex: M
Vaccine: COVID19
Symptoms: Chills, Erythema, Pain in jaw
Clinical narrative: JAW PAIN; REDNESS ON THE EARS; CHILLS; This spontaneous report received from a consumer concerned a male of unspecified age. The patient's height, and weight were not reported. The patient's concurrent conditions included temporomandibular joint disorder. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 08-MAR-2021 for prophylactic vaccination. Concomitant medications included diazepam for temporomandibular joint disorder. On 08-MAR-2021, the subject experienced chills. On 09-MAR-2021, the subject experienced jaw pain. On 09-MAR-2021, the subject experienced redness on the ears. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The batch number was not reported and has been requested. The patient recovered from chills on 09-MAR-2021, had not recovered from jaw pain, and the outcome of redness on the ears was not reported. This report was non-serious.
Sex: U
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: ARM WAS LITTLE SORE; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 11-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the subject experienced arm sore. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of arm sore was not reported. This report was non-serious.
Sex: U
Vaccine: COVID19
Symptoms: Anxiety, Disturbance in attention, Dizziness, Fatigue, Hypoaesthesia
Clinical narrative: VERTIGO; INABILITY TO CONCENTRATE; DIZZINESS; COULDN'T DRIVE FOR 2 HOURS; NUMBNESS LEFT ARM; PAIN UP AND DOWN LEFT SIDE OF THE BODY; ANXIETY; SWELLING LEFT ARM; NAUSEA; PAIN AT INJECTION SITE; FATIGUE; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805020, and expiry: UNKNOWN) dose was not reported, administered on 10-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 10-MAR-2021, the subject experienced vertigo. On 10-MAR-2021, the subject experienced inability to concentrate. On 10-MAR-2021, the subject experienced dizziness. On 10-MAR-2021, the subject experienced couldn't drive for 2 hours. On 10-MAR-2021, the subject experienced numbness left arm. On 10-MAR-2021, the subject experienced pain up and down left side of the body. On 10-MAR-2021, the subject experienced anxiety. On 10-MAR-2021, the subject experienced swelling left arm. On 10-MAR-2021, the subject experienced nausea. On 10-MAR-2021, the subject experienced pain at injection site. On 10-MAR-2021, the subject experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from vertigo on 12-MAR-2021, and inability to concentrate, dizziness, couldn't drive for 2 hours, numbness left arm, pain up and down left side of the body, swelling left arm, nausea, and fatigue on 10-MAR-2021, was recovering from pain at injection site, and had not recovered from anxiety. This report was non-serious.
Sex: U
Vaccine: COVID19
Symptoms: Impaired driving ability, Injection site pain, Injection site swelling, Nausea, Pain
Clinical narrative: VERTIGO; INABILITY TO CONCENTRATE; DIZZINESS; COULDN'T DRIVE FOR 2 HOURS; NUMBNESS LEFT ARM; PAIN UP AND DOWN LEFT SIDE OF THE BODY; ANXIETY; SWELLING LEFT ARM; NAUSEA; PAIN AT INJECTION SITE; FATIGUE; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805020, and expiry: UNKNOWN) dose was not reported, administered on 10-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 10-MAR-2021, the subject experienced vertigo. On 10-MAR-2021, the subject experienced inability to concentrate. On 10-MAR-2021, the subject experienced dizziness. On 10-MAR-2021, the subject experienced couldn't drive for 2 hours. On 10-MAR-2021, the subject experienced numbness left arm. On 10-MAR-2021, the subject experienced pain up and down left side of the body. On 10-MAR-2021, the subject experienced anxiety. On 10-MAR-2021, the subject experienced swelling left arm. On 10-MAR-2021, the subject experienced nausea. On 10-MAR-2021, the subject experienced pain at injection site. On 10-MAR-2021, the subject experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from vertigo on 12-MAR-2021, and inability to concentrate, dizziness, couldn't drive for 2 hours, numbness left arm, pain up and down left side of the body, swelling left arm, nausea, and fatigue on 10-MAR-2021, was recovering from pain at injection site, and had not recovered from anxiety. This report was non-serious.
Sex: U
Vaccine: COVID19
Symptoms: Vertigo
Clinical narrative: VERTIGO; INABILITY TO CONCENTRATE; DIZZINESS; COULDN'T DRIVE FOR 2 HOURS; NUMBNESS LEFT ARM; PAIN UP AND DOWN LEFT SIDE OF THE BODY; ANXIETY; SWELLING LEFT ARM; NAUSEA; PAIN AT INJECTION SITE; FATIGUE; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805020, and expiry: UNKNOWN) dose was not reported, administered on 10-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 10-MAR-2021, the subject experienced vertigo. On 10-MAR-2021, the subject experienced inability to concentrate. On 10-MAR-2021, the subject experienced dizziness. On 10-MAR-2021, the subject experienced couldn't drive for 2 hours. On 10-MAR-2021, the subject experienced numbness left arm. On 10-MAR-2021, the subject experienced pain up and down left side of the body. On 10-MAR-2021, the subject experienced anxiety. On 10-MAR-2021, the subject experienced swelling left arm. On 10-MAR-2021, the subject experienced nausea. On 10-MAR-2021, the subject experienced pain at injection site. On 10-MAR-2021, the subject experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from vertigo on 12-MAR-2021, and inability to concentrate, dizziness, couldn't drive for 2 hours, numbness left arm, pain up and down left side of the body, swelling left arm, nausea, and fatigue on 10-MAR-2021, was recovering from pain at injection site, and had not recovered from anxiety. This report was non-serious.
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Pain
Clinical narrative: BODY ACHES; CHILLS; TIRED; SEVERE HEADACHES; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 12-MAR-2021 11:30 for prophylactic vaccination.The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On MAR-2021, the subject experienced body aches. On MAR-2021, the subject experienced chills. On MAR-2021, the subject experienced tired. On MAR-2021, the subject experienced severe headaches. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the body aches, tired, severe headaches and chills was not reported. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Body temperature, Chills, Disturbance in attention, Dizziness
Clinical narrative: RASPY VOICE; FEVER; CHILLS; HEADACHE; HIVES; RASH-SPIDER VEINS; NAUSEA; BODY ACHES; NO ENERGY; DIZZINESS; DIFFICULTY CONCENTRATING; This spontaneous report received from a patient concerned a 67 year old female. The patient's height, and weight were not reported. The patient's past medical history included allergy to prevnar 13, allergies to shingles shot, osteoarthritis, statin allergy, environmental allergy, shellfish allergy, iodine allergy, beef allergy, and gallidium allergy. The patient was previously treated with pneumococcal vaccine conj 7v (crm197) for prophylactic vaccination.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown, expiry: UNKNOWN) dose was not reported, administered on 10-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 10-MAR-2021, the subject experienced hives. On 10-MAR-2021, the subject experienced rash-spider veins. On 10-MAR-2021, the subject experienced nausea. On 10-MAR-2021, the subject experienced body aches. On 10-MAR-2021, the subject experienced no energy. On 10-MAR-2021, the subject experienced dizziness. On 10-MAR-2021, the subject experienced difficulty concentrating. On 10-MAR-2021, the subject experienced fever. On 10-MAR-2021, the subject experienced chills. On 10-MAR-2021, the subject experienced headache. On 13-MAR-2021, the subject experienced raspy voice. Laboratory data (dates unspecified) included: Body temperature (NR: not provided) 101 Unit not reported. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from hives, and rash-spider veins, and had not recovered from headache, fever, chills, nausea, body aches, no energy, dizziness, difficulty concentrating, and raspy voice. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Dysphonia, Headache, Nausea, Pain, Pyrexia
Clinical narrative: RASPY VOICE; FEVER; CHILLS; HEADACHE; HIVES; RASH-SPIDER VEINS; NAUSEA; BODY ACHES; NO ENERGY; DIZZINESS; DIFFICULTY CONCENTRATING; This spontaneous report received from a patient concerned a 67 year old female. The patient's height, and weight were not reported. The patient's past medical history included allergy to prevnar 13, allergies to shingles shot, osteoarthritis, statin allergy, environmental allergy, shellfish allergy, iodine allergy, beef allergy, and gallidium allergy. The patient was previously treated with pneumococcal vaccine conj 7v (crm197) for prophylactic vaccination.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown, expiry: UNKNOWN) dose was not reported, administered on 10-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 10-MAR-2021, the subject experienced hives. On 10-MAR-2021, the subject experienced rash-spider veins. On 10-MAR-2021, the subject experienced nausea. On 10-MAR-2021, the subject experienced body aches. On 10-MAR-2021, the subject experienced no energy. On 10-MAR-2021, the subject experienced dizziness. On 10-MAR-2021, the subject experienced difficulty concentrating. On 10-MAR-2021, the subject experienced fever. On 10-MAR-2021, the subject experienced chills. On 10-MAR-2021, the subject experienced headache. On 13-MAR-2021, the subject experienced raspy voice. Laboratory data (dates unspecified) included: Body temperature (NR: not provided) 101 Unit not reported. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from hives, and rash-spider veins, and had not recovered from headache, fever, chills, nausea, body aches, no energy, dizziness, difficulty concentrating, and raspy voice. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Spider vein, Urticaria
Clinical narrative: RASPY VOICE; FEVER; CHILLS; HEADACHE; HIVES; RASH-SPIDER VEINS; NAUSEA; BODY ACHES; NO ENERGY; DIZZINESS; DIFFICULTY CONCENTRATING; This spontaneous report received from a patient concerned a 67 year old female. The patient's height, and weight were not reported. The patient's past medical history included allergy to prevnar 13, allergies to shingles shot, osteoarthritis, statin allergy, environmental allergy, shellfish allergy, iodine allergy, beef allergy, and gallidium allergy. The patient was previously treated with pneumococcal vaccine conj 7v (crm197) for prophylactic vaccination.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown, expiry: UNKNOWN) dose was not reported, administered on 10-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 10-MAR-2021, the subject experienced hives. On 10-MAR-2021, the subject experienced rash-spider veins. On 10-MAR-2021, the subject experienced nausea. On 10-MAR-2021, the subject experienced body aches. On 10-MAR-2021, the subject experienced no energy. On 10-MAR-2021, the subject experienced dizziness. On 10-MAR-2021, the subject experienced difficulty concentrating. On 10-MAR-2021, the subject experienced fever. On 10-MAR-2021, the subject experienced chills. On 10-MAR-2021, the subject experienced headache. On 13-MAR-2021, the subject experienced raspy voice. Laboratory data (dates unspecified) included: Body temperature (NR: not provided) 101 Unit not reported. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from hives, and rash-spider veins, and had not recovered from headache, fever, chills, nausea, body aches, no energy, dizziness, difficulty concentrating, and raspy voice. This report was non-serious.
Sex: U
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: HEADACHE; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: UNKNOWN and expiry: UNKNOWN) dose was not reported, administered on 13-MAR-2021 13:00 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 14-MAR-2021, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from headache. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Diarrhoea, Fatigue, Pain, Pain in extremity
Clinical narrative: DIARRHOEA; FATIGUE; LEFT ARM PAIN; STOMACH ACHE; ACHES; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805022, and batch number: 1805022 expiry: UNKNOWN) dose was not reported, administered on 10-MAR-2021 12:30 for prophylactic vaccination. No concomitant medications were reported. On 12-MAR-2021, the subject experienced diarrhoea. On 12-MAR-2021, the subject experienced fatigue. On 12-MAR-2021, the subject experienced left arm pain. On 12-MAR-2021, the subject experienced stomach ache. On 12-MAR-2021, the subject experienced aches. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from diarrhoea, aches, fatigue, left arm pain, and stomach ache. This report was non-serious.
Sex: U
Vaccine: COVID19
Symptoms: Chills, Headache, Pain, Pyrexia
Clinical narrative: BODY ACHES; CHILLS; HEADACHE; FEVER; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, once a total administered on 12-MAR-2021 to Left Arm for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On MAR-2021, the subject experienced body aches. On MAR-2021, the subject experienced chills. On MAR-2021, the subject experienced headache. On MAR-2021, the subject experienced fever. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the headache, chills, fever and body aches was not reported. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Chills, Nasopharyngitis, Rash
Clinical narrative: This spontaneous report received from a patient concerned a female of unspecified age. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included the patient was not pregnant at the time of reporting. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805029, and batch number: 1805029 expiry: UNKNOWN) dose was not reported, administered on 12-MAR-2021 16:00 for prophylactic vaccination. No concomitant medications were reported. On 12-MAR-2021, the subject experienced cold. On 12-MAR-2021, the subject experienced chills. On 12-MAR-2021, the subject experienced rash on her face, neck and chest. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the chills, cold and rash on her face, neck and chest was not reported. This report was non-serious.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Alanine aminotransferase, Aspartate aminotransferase, Blood alkaline phosphatase, Blood bilirubin, Blood pressure diastolic
Clinical narrative: EXTREME DIZZINESS; HIGH BLOOD PRESSURE; VOMITED 3 TIMES; FOUR BOWEL MOVEMENTS; HYPERGLYCEMIA; NAUSEA; This spontaneous report received from a patient concerned a 79 year old female. The patient's weight was 65.5 kilograms, and height was 157.48 centimeters. The patient's concurrent conditions included high blood pressure, elevated cholesterol, non-smoker, alcohol user, hyperlipidemia, and hypertension, and other pre-existing medical conditions included patient had no drug abuse. The patient was previously treated with codeine, and acetylsalicylic acid.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 10-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. Concomitant medications included nebivolol hydrochloride for high blood pressure.  On 13-MAR-2021, the subject experienced extreme dizziness. On 13-MAR-2021, the subject experienced high blood pressure. On 13-MAR-2021, the subject experienced vomited 3 times. On 13-MAR-2021, the subject experienced four bowel movements. On 13-MAR-2021, the subject experienced hyperglycemia. On 13-MAR-2021, the subject experienced nausea. Laboratory data included: Alanine aminotransferase (NR: not provided) 52 IU/L, Alkaline phosphatase (NR: not provided) 80 IU/L, Aspartate aminotransferase (NR: not provided) 42 IU/L, Bilirubin total (NR: not provided) 1.2 mg/dL, Blood test (NR: not provided) Normal, Body temperature (NR: not provided) 34.4 F, Brain natriuretic peptide (NR: not provided) 34 pg/mL, Chest X-ray (NR: not provided) Normal, Diastolic blood pressure (NR: not provided) 99, 88, 68, 59, 43, 67, 57 mmHg, Heart rate (NR: not provided) 70bpm, 65 bpm, High sensitive troponin I (NR: not provided) <0.003 ng/mL, Oxygen saturation (NR: not provided) 92, 91, 93, 91 %, Respiratory rate (NR: not provided), Systolic blood pressure (NR: not provided) 250, 160, 130, 96, 103, 150, 130 mmHg, and Urinalysis (NR: not provided) Normal. On 13-MAR-2021 11:38, Laboratory data included: Pulse rate (NR: not provided) 62 pm. Treatment medications (dates unspecified) included: hydrochlorothiazide/triamterene, valsartan, omega-3 triglycerides, oyster shell, diclofenac, celecoxib, potassium chloride, ubidecarenone, xantofyl/zeaxanthin, simvastatin, and ascorbic acid/betacarotene/biotin/calcium/chlorine/chromium/copper/cyanocobalamin/dl-alpha tocopheryl acetate/folic acid/iodine/magnesium/manganese/molybdenum/nickel/nicotinamide/pantothenic acid/phosphorus/phytomenadione/potassium/pyridoxine hydrochloride/retinol/riboflavin/selenium/silicon/thiamine/vanadium/vitamin d nos/xantofyl/zinc. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from extreme dizziness, high blood pressure, vomited 3 times, and nausea on 16-MAR-2021, and the outcome of four bowel movements and hyperglycemia was not reported. This report was non-serious.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure systolic, Blood test, Body temperature, Brain natriuretic peptide, Chest X-ray
Clinical narrative: EXTREME DIZZINESS; HIGH BLOOD PRESSURE; VOMITED 3 TIMES; FOUR BOWEL MOVEMENTS; HYPERGLYCEMIA; NAUSEA; This spontaneous report received from a patient concerned a 79 year old female. The patient's weight was 65.5 kilograms, and height was 157.48 centimeters. The patient's concurrent conditions included high blood pressure, elevated cholesterol, non-smoker, alcohol user, hyperlipidemia, and hypertension, and other pre-existing medical conditions included patient had no drug abuse. The patient was previously treated with codeine, and acetylsalicylic acid.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 10-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. Concomitant medications included nebivolol hydrochloride for high blood pressure.  On 13-MAR-2021, the subject experienced extreme dizziness. On 13-MAR-2021, the subject experienced high blood pressure. On 13-MAR-2021, the subject experienced vomited 3 times. On 13-MAR-2021, the subject experienced four bowel movements. On 13-MAR-2021, the subject experienced hyperglycemia. On 13-MAR-2021, the subject experienced nausea. Laboratory data included: Alanine aminotransferase (NR: not provided) 52 IU/L, Alkaline phosphatase (NR: not provided) 80 IU/L, Aspartate aminotransferase (NR: not provided) 42 IU/L, Bilirubin total (NR: not provided) 1.2 mg/dL, Blood test (NR: not provided) Normal, Body temperature (NR: not provided) 34.4 F, Brain natriuretic peptide (NR: not provided) 34 pg/mL, Chest X-ray (NR: not provided) Normal, Diastolic blood pressure (NR: not provided) 99, 88, 68, 59, 43, 67, 57 mmHg, Heart rate (NR: not provided) 70bpm, 65 bpm, High sensitive troponin I (NR: not provided) <0.003 ng/mL, Oxygen saturation (NR: not provided) 92, 91, 93, 91 %, Respiratory rate (NR: not provided), Systolic blood pressure (NR: not provided) 250, 160, 130, 96, 103, 150, 130 mmHg, and Urinalysis (NR: not provided) Normal. On 13-MAR-2021 11:38, Laboratory data included: Pulse rate (NR: not provided) 62 pm. Treatment medications (dates unspecified) included: hydrochlorothiazide/triamterene, valsartan, omega-3 triglycerides, oyster shell, diclofenac, celecoxib, potassium chloride, ubidecarenone, xantofyl/zeaxanthin, simvastatin, and ascorbic acid/betacarotene/biotin/calcium/chlorine/chromium/copper/cyanocobalamin/dl-alpha tocopheryl acetate/folic acid/iodine/magnesium/manganese/molybdenum/nickel/nicotinamide/pantothenic acid/phosphorus/phytomenadione/potassium/pyridoxine hydrochloride/retinol/riboflavin/selenium/silicon/thiamine/vanadium/vitamin d nos/xantofyl/zinc. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from extreme dizziness, high blood pressure, vomited 3 times, and nausea on 16-MAR-2021, and the outcome of four bowel movements and hyperglycemia was not reported. This report was non-serious.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Frequent bowel movements, Heart rate, Hyperglycaemia, Hypertension
Clinical narrative: EXTREME DIZZINESS; HIGH BLOOD PRESSURE; VOMITED 3 TIMES; FOUR BOWEL MOVEMENTS; HYPERGLYCEMIA; NAUSEA; This spontaneous report received from a patient concerned a 79 year old female. The patient's weight was 65.5 kilograms, and height was 157.48 centimeters. The patient's concurrent conditions included high blood pressure, elevated cholesterol, non-smoker, alcohol user, hyperlipidemia, and hypertension, and other pre-existing medical conditions included patient had no drug abuse. The patient was previously treated with codeine, and acetylsalicylic acid.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 10-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. Concomitant medications included nebivolol hydrochloride for high blood pressure.  On 13-MAR-2021, the subject experienced extreme dizziness. On 13-MAR-2021, the subject experienced high blood pressure. On 13-MAR-2021, the subject experienced vomited 3 times. On 13-MAR-2021, the subject experienced four bowel movements. On 13-MAR-2021, the subject experienced hyperglycemia. On 13-MAR-2021, the subject experienced nausea. Laboratory data included: Alanine aminotransferase (NR: not provided) 52 IU/L, Alkaline phosphatase (NR: not provided) 80 IU/L, Aspartate aminotransferase (NR: not provided) 42 IU/L, Bilirubin total (NR: not provided) 1.2 mg/dL, Blood test (NR: not provided) Normal, Body temperature (NR: not provided) 34.4 F, Brain natriuretic peptide (NR: not provided) 34 pg/mL, Chest X-ray (NR: not provided) Normal, Diastolic blood pressure (NR: not provided) 99, 88, 68, 59, 43, 67, 57 mmHg, Heart rate (NR: not provided) 70bpm, 65 bpm, High sensitive troponin I (NR: not provided) <0.003 ng/mL, Oxygen saturation (NR: not provided) 92, 91, 93, 91 %, Respiratory rate (NR: not provided), Systolic blood pressure (NR: not provided) 250, 160, 130, 96, 103, 150, 130 mmHg, and Urinalysis (NR: not provided) Normal. On 13-MAR-2021 11:38, Laboratory data included: Pulse rate (NR: not provided) 62 pm. Treatment medications (dates unspecified) included: hydrochlorothiazide/triamterene, valsartan, omega-3 triglycerides, oyster shell, diclofenac, celecoxib, potassium chloride, ubidecarenone, xantofyl/zeaxanthin, simvastatin, and ascorbic acid/betacarotene/biotin/calcium/chlorine/chromium/copper/cyanocobalamin/dl-alpha tocopheryl acetate/folic acid/iodine/magnesium/manganese/molybdenum/nickel/nicotinamide/pantothenic acid/phosphorus/phytomenadione/potassium/pyridoxine hydrochloride/retinol/riboflavin/selenium/silicon/thiamine/vanadium/vitamin d nos/xantofyl/zinc. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from extreme dizziness, high blood pressure, vomited 3 times, and nausea on 16-MAR-2021, and the outcome of four bowel movements and hyperglycemia was not reported. This report was non-serious.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Oxygen saturation, Respiratory rate, Troponin I, Urine analysis
Clinical narrative: EXTREME DIZZINESS; HIGH BLOOD PRESSURE; VOMITED 3 TIMES; FOUR BOWEL MOVEMENTS; HYPERGLYCEMIA; NAUSEA; This spontaneous report received from a patient concerned a 79 year old female. The patient's weight was 65.5 kilograms, and height was 157.48 centimeters. The patient's concurrent conditions included high blood pressure, elevated cholesterol, non-smoker, alcohol user, hyperlipidemia, and hypertension, and other pre-existing medical conditions included patient had no drug abuse. The patient was previously treated with codeine, and acetylsalicylic acid.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 10-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. Concomitant medications included nebivolol hydrochloride for high blood pressure.  On 13-MAR-2021, the subject experienced extreme dizziness. On 13-MAR-2021, the subject experienced high blood pressure. On 13-MAR-2021, the subject experienced vomited 3 times. On 13-MAR-2021, the subject experienced four bowel movements. On 13-MAR-2021, the subject experienced hyperglycemia. On 13-MAR-2021, the subject experienced nausea. Laboratory data included: Alanine aminotransferase (NR: not provided) 52 IU/L, Alkaline phosphatase (NR: not provided) 80 IU/L, Aspartate aminotransferase (NR: not provided) 42 IU/L, Bilirubin total (NR: not provided) 1.2 mg/dL, Blood test (NR: not provided) Normal, Body temperature (NR: not provided) 34.4 F, Brain natriuretic peptide (NR: not provided) 34 pg/mL, Chest X-ray (NR: not provided) Normal, Diastolic blood pressure (NR: not provided) 99, 88, 68, 59, 43, 67, 57 mmHg, Heart rate (NR: not provided) 70bpm, 65 bpm, High sensitive troponin I (NR: not provided) <0.003 ng/mL, Oxygen saturation (NR: not provided) 92, 91, 93, 91 %, Respiratory rate (NR: not provided), Systolic blood pressure (NR: not provided) 250, 160, 130, 96, 103, 150, 130 mmHg, and Urinalysis (NR: not provided) Normal. On 13-MAR-2021 11:38, Laboratory data included: Pulse rate (NR: not provided) 62 pm. Treatment medications (dates unspecified) included: hydrochlorothiazide/triamterene, valsartan, omega-3 triglycerides, oyster shell, diclofenac, celecoxib, potassium chloride, ubidecarenone, xantofyl/zeaxanthin, simvastatin, and ascorbic acid/betacarotene/biotin/calcium/chlorine/chromium/copper/cyanocobalamin/dl-alpha tocopheryl acetate/folic acid/iodine/magnesium/manganese/molybdenum/nickel/nicotinamide/pantothenic acid/phosphorus/phytomenadione/potassium/pyridoxine hydrochloride/retinol/riboflavin/selenium/silicon/thiamine/vanadium/vitamin d nos/xantofyl/zinc. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from extreme dizziness, high blood pressure, vomited 3 times, and nausea on 16-MAR-2021, and the outcome of four bowel movements and hyperglycemia was not reported. This report was non-serious.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: EXTREME DIZZINESS; HIGH BLOOD PRESSURE; VOMITED 3 TIMES; FOUR BOWEL MOVEMENTS; HYPERGLYCEMIA; NAUSEA; This spontaneous report received from a patient concerned a 79 year old female. The patient's weight was 65.5 kilograms, and height was 157.48 centimeters. The patient's concurrent conditions included high blood pressure, elevated cholesterol, non-smoker, alcohol user, hyperlipidemia, and hypertension, and other pre-existing medical conditions included patient had no drug abuse. The patient was previously treated with codeine, and acetylsalicylic acid.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 10-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. Concomitant medications included nebivolol hydrochloride for high blood pressure.  On 13-MAR-2021, the subject experienced extreme dizziness. On 13-MAR-2021, the subject experienced high blood pressure. On 13-MAR-2021, the subject experienced vomited 3 times. On 13-MAR-2021, the subject experienced four bowel movements. On 13-MAR-2021, the subject experienced hyperglycemia. On 13-MAR-2021, the subject experienced nausea. Laboratory data included: Alanine aminotransferase (NR: not provided) 52 IU/L, Alkaline phosphatase (NR: not provided) 80 IU/L, Aspartate aminotransferase (NR: not provided) 42 IU/L, Bilirubin total (NR: not provided) 1.2 mg/dL, Blood test (NR: not provided) Normal, Body temperature (NR: not provided) 34.4 F, Brain natriuretic peptide (NR: not provided) 34 pg/mL, Chest X-ray (NR: not provided) Normal, Diastolic blood pressure (NR: not provided) 99, 88, 68, 59, 43, 67, 57 mmHg, Heart rate (NR: not provided) 70bpm, 65 bpm, High sensitive troponin I (NR: not provided) <0.003 ng/mL, Oxygen saturation (NR: not provided) 92, 91, 93, 91 %, Respiratory rate (NR: not provided), Systolic blood pressure (NR: not provided) 250, 160, 130, 96, 103, 150, 130 mmHg, and Urinalysis (NR: not provided) Normal. On 13-MAR-2021 11:38, Laboratory data included: Pulse rate (NR: not provided) 62 pm. Treatment medications (dates unspecified) included: hydrochlorothiazide/triamterene, valsartan, omega-3 triglycerides, oyster shell, diclofenac, celecoxib, potassium chloride, ubidecarenone, xantofyl/zeaxanthin, simvastatin, and ascorbic acid/betacarotene/biotin/calcium/chlorine/chromium/copper/cyanocobalamin/dl-alpha tocopheryl acetate/folic acid/iodine/magnesium/manganese/molybdenum/nickel/nicotinamide/pantothenic acid/phosphorus/phytomenadione/potassium/pyridoxine hydrochloride/retinol/riboflavin/selenium/silicon/thiamine/vanadium/vitamin d nos/xantofyl/zinc. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from extreme dizziness, high blood pressure, vomited 3 times, and nausea on 16-MAR-2021, and the outcome of four bowel movements and hyperglycemia was not reported. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: SORENESS; This spontaneous report received from a patient concerned a female of unspecified age. The patient's height, and weight were not reported. The patient's concurrent conditions included spinal cord degeneration.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 11-MAR-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. Concomitant medications included morphine for spinal cord degeneration. On MAR-2021, the subject experienced soreness. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from soreness. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Body temperature, Chills, Headache, Myalgia
Clinical narrative: Muscle pain; skin tenderness; BACKACHE; chills; FEVER (100.2); headache; MILD NAUSEA; This spontaneous report received from a patient concerned a 58 year old female. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 13-MAR-2021 13:30 for prophylactic vaccination. The batch number was not reported. The Company was unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On MAR-2021, the subject experienced backache. On MAR-2021, the subject experienced chills. On MAR-2021, the subject experienced fever (100.2). On MAR-2021, the subject experienced headache. On MAR-2021, the subject experienced mild nausea. Laboratory data included: Body temperature (NR: not provided) 100.2. Treatment medications included: paracetamol. On 13-MAR-2021, the subject experienced skin tenderness. On 13-MAR-2021, the subject experienced muscle pain. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from skin tenderness, chills, muscle pain, and fever (100.2) on MAR-2021, and had not recovered from headache, backache, and mild nausea. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain of skin, Pyrexia
Clinical narrative: Muscle pain; skin tenderness; BACKACHE; chills; FEVER (100.2); headache; MILD NAUSEA; This spontaneous report received from a patient concerned a 58 year old female. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 13-MAR-2021 13:30 for prophylactic vaccination. The batch number was not reported. The Company was unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On MAR-2021, the subject experienced backache. On MAR-2021, the subject experienced chills. On MAR-2021, the subject experienced fever (100.2). On MAR-2021, the subject experienced headache. On MAR-2021, the subject experienced mild nausea. Laboratory data included: Body temperature (NR: not provided) 100.2. Treatment medications included: paracetamol. On 13-MAR-2021, the subject experienced skin tenderness. On 13-MAR-2021, the subject experienced muscle pain. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from skin tenderness, chills, muscle pain, and fever (100.2) on MAR-2021, and had not recovered from headache, backache, and mild nausea. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: FEVER; This spontaneous report received from a patient via a company representative concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on MAR-2021 for prophylactic vaccination. No concomitant medications were reported. The batch number was not reported. The company is unable to perform follow-up to request batch/lot no. On MAR-2021, the subject experienced fever.  The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of fever was not reported. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pain
Clinical narrative: BODY ACHES; CHILLS; FATIGUE; This spontaneous report received from a consumer via a company representative concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on MAR-2021 for prophylactic vaccination. The batch number was not reported. we are unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On 14-MAR-2021, the subject experienced body aches. On 14-MAR-2021, the subject experienced chills. On 14-MAR-2021, the subject experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the body aches, fatigue and chills was not reported. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Hypoaesthesia, Pyrexia
Clinical narrative: NUMB ARM; HEADACHE; CHILLS; FEVER; This spontaneous report received from a patient concerned a female of unspecified age. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included patient stated having no medical problems and have no known allergies. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805022 expiry: 25/MAY/2021) dose was not reported, administered on 13-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 14-MAR-2021, the subject experienced numb arm. On 14-MAR-2021, the subject experienced headache. On 14-MAR-2021, the subject experienced chills. On 14-MAR-2021, the subject experienced fever. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever on MAR-2021, was recovering from headache, and numb arm, and had not recovered from chills. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Chills, Herpes zoster, Pyrexia
Clinical narrative: SHINGLES RASH; FEVER; CHILLS; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805022,expiry: UNKNOWN) dose was not reported, administered on 11-MAR-2021 17:15 for prophylactic vaccination. No concomitant medications were reported. On 12-MAR-2021, the subject experienced fever. On 12-MAR-2021, the subject experienced chills. On 14-MAR-2021, the subject experienced shingles rash. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever on -MAR-2021, and chills on 12-MAR-2021, and had not recovered from shingles rash. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Bone pain, Headache, Malaise, Nausea, Pyrexia
Clinical narrative: ACHY BONES; GENERAL  MALAISE; NAUSEA; FEVER; HEADACHE; This spontaneous report received from a patient via a company representative concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. No concomitant medications were reported. On 14-MAR-2021, the subject experienced achy bones. On 14-MAR-2021, the subject experienced general malaise. On 14-MAR-2021, the subject experienced nausea. On 14-MAR-2021, the subject experienced fever. On 14-MAR-2021, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the general malaise, nausea, fever, achy bones and headache was not reported. This report was non-serious.
Sex: U
Vaccine: COVID19
Symptoms: Pain, Pyrexia
Clinical narrative: BODY ACHE; FEVER; This spontaneous report received from a vaccine facility concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 2021 for prophylactic vaccination. The batch number was not reported. We are unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On 2021, the subject experienced body ache. On 2021, the subject experienced fever. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the fever and body ache was not reported. This report was non-serious.
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Insomnia, Pain, Pyrexia
Clinical narrative: BODY ACHE; NO SLEEP; FEVER; HEADACHE; CHILLS; This spontaneous report received from a patient via a company representative concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 10-MAR-2021 for prophylactic vaccination. The batch number was not reported. Per procedure no follow up will be requested for this case. No concomitant medications were reported. On an unspecified date, the subject experienced body ache, no sleep, fever, headache, and chills. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the fever, headache, body ache, chills and no sleep was not reported. This report was non-serious.